GlassScriptPhysician profile
Martin Ruiz
NPI 1356410104
$4,791.72
in general payments reported to CMS, 2019-2025
32 companies · $70.47 in 2025
The $70.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $376 · 2021: $350 · 2022: $731 · 2023: $1,062 · 2024: $572 · 2025: $70.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $985.32 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $646.37 | 2019-2024 | Mounjaro, Jardiance, Kisunla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $607.53 | 2020-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $382.77 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.30 | 2019-2023 | Tradjenta, Jardiance |
| Janssen Pharmaceuticals, INC | $249.12 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $229.52 | 2022-2024 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $176.02 | 2022 | |
| Medtronic, INC. | $162.92 | 2021-2023 | Micra |
| Axonics, INC. | $136.98 | 2022 | |
| Inspire Medical Systems, INC. | $118.21 | 2023 | Inspire |
| Janssen Scientific Affairs, LLC | $117.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $107.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $81.50 | 2021-2024 | |
| Eisai INC. | $70.77 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.83 | 2019 | |
| Abbott Laboratories | $52.22 | 2019-2024 | Cardiomems |
| Merck Sharp & Dohme LLC | $45.72 | 2019-2021 | |
| Pfizer INC. | $39.49 | 2019-2020 | |
| Corcept Therapeutics | $38.53 | 2022-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $35.66 | 2021-2023 | Gvoke Hypopen |
| Dexcom, INC. | $31.21 | 2021 | |
| Astellas Pharma US INC | $23.64 | 2019 | |
| Bardy Diagnostics, INC. | $21.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.39 | 2019 | |
| Tandem Diabetes Care, INC. | $17.70 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Jazz Pharmaceuticals INC. | $15.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.19 | 2021 | |
| Currax Pharmaceuticals LLC | $14.35 | 2023 | Contrave |
| Medtronic Minimed, INC. | $14.24 | 2020 | |
| Insulet Corporation | $13.67 | 2021 | |
| Mannkind Corporation | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.